Suven Life Sciences Ltd (SUVP)

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer’s disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7 Antagonist for pain and inflammation indications; Multimodal Dual 5-HT2A Antagonist and 5-HT1A Agonist for psychosis and depression indications; 5-HT1A Agonist for treatment resistant depression; Multimodal Dual 5-HT2A Antagonist and SRI for bipolar disorders, and depression and schizophrenia; and M1 PAM for gastrointestinal disorder indications. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.